Gilead files for filgotinib in Japan; Alzheimer's flop forces some painful next steps at Neurotrope
→ Gilead has been right on the heels of its rival AbbVie with its JAK-inhibitor filgotinib. The company has now submitted an NDA for the drug to the Japanese Ministry of Health, Labor and Welfare for the treatment of adults with rheumatoid arthritis (RA). The submission is backed by data from the phase III FINCH trial, where “once-daily treatment with filgotinib demonstrated the potential to improve clinical signs and symptoms, to achieve low disease activity and remission and to inhibit structural damage for patients living with RA.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.